Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 11.62
- Piotroski Score 2.00
- Grade Buy
- Symbol (RCKT)
- Company Rocket Pharmaceuticals, Inc.
- Price $18.47
- Changes Percentage (4.95%)
- Change $0.87
- Day Low $17.80
- Day High $18.78
- Year High $32.53
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/03/2024
- Fiscal Year End N/A
- Average Stock Price Target $39.00
- High Stock Price Target $69.00
- Low Stock Price Target $34.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.85
- Trailing P/E Ratio -7.96
- Forward P/E Ratio -7.96
- P/E Growth -7.96
- Net Income $-245,595,000
Income Statement
Quarterly
Annual
Latest News of RCKT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Rocket Pharmaceuticals, Inc. (RCKT) Stock Price, News, Quote & History - Yahoo Finance
Morgan Stanley predicts a substantial increase of up to 220% for two 'Strong Buy' stocks. Investor sentiment has remained strong, with the S&P 500 rallying 9% since its August low, driven by positive ...
By Yahoo! Finance | 1 month ago
